BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 12,540 shares of BioLife Solutions stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $19.50, for a total value of $244,530.00. Following the sale, the chief executive officer now directly owns 152,057 shares of the company’s stock, valued at $2,965,111.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Michael Rice also recently made the following trade(s):

  • On Monday, July 16th, Michael Rice sold 12,540 shares of BioLife Solutions stock. The stock was sold at an average price of $19.90, for a total value of $249,546.00.
  • On Monday, June 18th, Michael Rice sold 12,540 shares of BioLife Solutions stock. The stock was sold at an average price of $12.89, for a total value of $161,640.60.

Shares of NASDAQ BLFS opened at $19.75 on Friday. The stock has a market cap of $324.63 million, a price-to-earnings ratio of -94.05 and a beta of 0.64. BioLife Solutions Inc has a 1 year low of $3.68 and a 1 year high of $22.86.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.01. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.20 million. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%. sell-side analysts predict that BioLife Solutions Inc will post 0.14 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of BioLife Solutions during the second quarter worth about $173,000. Granahan Investment Management Inc. MA acquired a new stake in shares of BioLife Solutions during the second quarter worth about $1,361,000. Sandler Capital Management acquired a new stake in shares of BioLife Solutions during the second quarter worth about $1,723,000. Manatuck Hill Partners LLC increased its position in shares of BioLife Solutions by 28.4% during the second quarter. Manatuck Hill Partners LLC now owns 64,200 shares of the medical equipment provider’s stock worth $733,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Shepherd Kaplan Krochuk LLC acquired a new stake in shares of BioLife Solutions during the second quarter worth about $183,000. 16.34% of the stock is owned by institutional investors.

A number of analysts have issued reports on BLFS shares. Maxim Group set a $9.00 price target on BioLife Solutions and gave the stock a “buy” rating in a report on Monday, April 30th. ValuEngine raised BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Friday, May 4th. B. Riley started coverage on BioLife Solutions in a report on Thursday, June 7th. They set a “buy” rating and a $14.00 price target for the company. Finally, Northland Securities reaffirmed a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a report on Friday, August 10th.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Featured Article: Market Capitalization in the Stock Market

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.